Anti-viral therapy using lamivudine and thymosin is helpful to prevent recurrence in hepatocellular carcinoma with coexisting active hepatitis B.
- Author:
Shu-qun CHENG
1
;
Meng-chao WU
;
Han CHEN
;
Feng SHEN
;
Jia-he YANG
;
Wen-ming CONG
;
Yu-xiang ZHAO
;
Pei-jun WANG
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Aged; Carcinoma, Hepatocellular; surgery; therapy; virology; DNA, Viral; drug effects; Female; Hepatectomy; methods; Hepatitis B; genetics; therapy; Humans; Lamivudine; therapeutic use; Liver Neoplasms; surgery; therapy; virology; Male; Middle Aged; Neoplasm Recurrence, Local; prevention & control; Postoperative Period; Reverse Transcriptase Inhibitors; therapeutic use; Survival Rate; Thymosin; analogs & derivatives; therapeutic use
- From: Chinese Journal of Oncology 2005;27(2):114-116
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the effect of postoperative anti-viral therapy using lamivudine and thymosin alpha1 on recurrence of hepatocellular carcinoma (HCC) coexisting with active hepatitis B.
METHODSFrom Jan. 2000 to Dec. 2002, 33 HCC patients with coexisting with active hepatitis B were randomized into two groups: Group I (n = 17) received hepatectomy only, and Group II (n = 16) received hepatectomy and postoperative therapy using lamivudine plus thymosin alpha1. The suppression of HBV-DNA, HBeAg seroconversion rate, tumor recurrence rate and median survival in the two groups were observed and compared.
RESULTSIn Group II and Group I, the 1-year HBV-DNA suppression rate was 100.0% vs 6.0% (P < 0.01), HBeAg seroconversion rate was 62.5% vs 5.9% (P < 0.05), tumor recurrence rate was 81.3% vs 95.5% (P > 0.05), the recurrence time was 7.0 vs 5.0 months (P < 0.01) and median survival 10.0 vs 7.0 months (P < 0.01).
CONCLUSIONAnti-viral therapy using lamivudine and thymosin alpha1 postoperatively may suppress the HBV reaction, delay the recurrence and prolong the survival for patients with HCC with coexisting active hepatitis B.
